168 related articles for article (PubMed ID: 25135996)
21. Oxaliplatin-induced neuropathy: a tale of two electrolytes.
Babiker HM; Green MR; Nelson MA; Elquza E
Support Care Cancer; 2015 Jun; 23(6):1483-5. PubMed ID: 25801447
[No Abstract] [Full Text] [Related]
22. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
Gamelin L; Boisdron-Celle M; Delva R; Guérin-Meyer V; Ifrah N; Morel A; Gamelin E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4055-61. PubMed ID: 15217938
[TBL] [Abstract][Full Text] [Related]
23. Atypical presentation of acute neurotoxicity secondary to oxaliplatin.
Uña E
J Oncol Pharm Pract; 2010 Dec; 16(4):280-2. PubMed ID: 20015928
[TBL] [Abstract][Full Text] [Related]
24. Xaliproden lessens oxaliplatin-mediated neuropathy.
Susman E
Lancet Oncol; 2006 Apr; 7(4):288. PubMed ID: 16598880
[No Abstract] [Full Text] [Related]
25. Oxaliplatin-related neurotoxicity: is chelation the solution?
Hoff PM
Nat Clin Pract Oncol; 2004 Dec; 1(2):78-9. PubMed ID: 16264824
[No Abstract] [Full Text] [Related]
26. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
Kurniali PC; Luo LG; Weitberg AB
Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
[TBL] [Abstract][Full Text] [Related]
27. Recurrent priapism related to oxaliplatin infusion.
Adenis A; Mailliez A; Rigot JM; Gamelin L; Vanhuyse M; Gamelin E
J Clin Oncol; 2008 Feb; 26(6):1016-7. PubMed ID: 18281680
[No Abstract] [Full Text] [Related]
28. Oxaliplatin-related neurotoxicity: how and why?
Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
[TBL] [Abstract][Full Text] [Related]
29. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
[TBL] [Abstract][Full Text] [Related]
30. [Peripheral neuropathy induced by anticancer drugs].
Oishi R; Egashira N
Fukuoka Igaku Zasshi; 2013 May; 104(5):71-80. PubMed ID: 23885391
[No Abstract] [Full Text] [Related]
31. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer.
Choi J; Kong K; Mozaffar T; Holcombe RF
Anticancer Drugs; 2006 Jan; 17(1):103-5. PubMed ID: 16317297
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers.
Xu XT; Dai ZH; Xu Q; Qiao YQ; Gu Y; Nie F; Zhu MM; Tong JL; Ran ZH
J Dig Dis; 2013 Jun; 14(6):288-98. PubMed ID: 23432969
[TBL] [Abstract][Full Text] [Related]
33. [Genetic backgrounds of peripheral neuropathy induced by oxaliplatin].
Mitsuma A; Ando Y
Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):62-5. PubMed ID: 23391543
[No Abstract] [Full Text] [Related]
34. Oxaliplatin-safety profile: neurotoxicity.
Grothey A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
[TBL] [Abstract][Full Text] [Related]
35. Interstitial lung disease associated with oxaliplatin: description of two cases.
Pena Alvarez C; Suh Oh HJ; Sáenz de Miera Rodríguez A; García Arroyo FR; Covela Rúa M; Salgado Boquete L; López Clemente PM; Constenla Figueiras M
Clin Transl Oncol; 2009 May; 11(5):332-3. PubMed ID: 19451069
[No Abstract] [Full Text] [Related]
36. [Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].
Kowalski T; Maier C; Reinacher-Schick A; Schlegel U
Schmerz; 2008 Feb; 22(1):16-23. PubMed ID: 17578604
[TBL] [Abstract][Full Text] [Related]
37. Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer.
Zhang X; Chen H; Lu Y; Xu C; Yao W; Xu L; Zhang R; Zhang L; Yao Q
Medicine (Baltimore); 2020 Dec; 99(50):e23564. PubMed ID: 33327312
[TBL] [Abstract][Full Text] [Related]
38. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
Guo Y; Jones D; Palmer JL; Forman A; Dakhil SR; Velasco MR; Weiss M; Gilman P; Mills GM; Noga SJ; Eng C; Overman MJ; Fisch MJ
Support Care Cancer; 2014 May; 22(5):1223-31. PubMed ID: 24362907
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy.
Gamelin L; Boisdron-Celle M; Morel A; Poirier AL; Berger V; Gamelin E; Tournigand C; de Gramont A
J Clin Oncol; 2008 Mar; 26(7):1188-9; author reply 1189-90. PubMed ID: 18309961
[No Abstract] [Full Text] [Related]
40. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
Argyriou AA; Chroni E; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP
Neurology; 2006 Dec; 67(12):2253-5. PubMed ID: 17190958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
